CSL Of Australia Raises Equity Funds Ahead of U.S. Merger Approval
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL drug maker has gone ahead with assertive equity-raising efforts even though the U.S. Federal Trade Commission could still block its planned $3.5 billion acquisition of Talecris Biotherapeutics. In less than a week after the deal was announced, CSL raised $1.53 billion to buy the firm from its owners, Cerberus Partners and Ampersand Ventures. Some analysts believe the FTC will order some divestments of human plasma products before approving the merger. One problem could be Talecris's Gamunex, with has a 24 percent market share, the same as CSL and its own products, amounting to a combined 48 percent compared with Baxter International's market-leading 35 percent. (Click here for more
You may also be interested in...
GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim
Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.
Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC
The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.
Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.
Need a specific report? 1000+ reports available
Buy Reports